Blood, 2022-11, Vol.140 (Supplement 1), p.391-393
- Bahlis, Nizar Jacques
- Tomasson, Michael H.
- Mohty, Mohamad
- Niesvizky, Ruben
- Nooka, Ajay K.
- Manier, Salomon
- Maisel, Christopher
- Jethava, Yogesh
- Martinez-Lopez, Joaquin
- Prince, H Miles
- Arnulf, Bertrand
- Rodriguez Otero, Paula
- Koehne, Guenther
- Touzeau, Cyrille
- Raje, Noopur
- Iida, Shinsuke
- Raab, Marc-Steffen
- Leip, Eric
- Sullivan, Sharon
- Conte, Umberto
- Viqueira, Andrea
- Lesokhin, Alexander M
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Bahlis, Nizar Jacques
- Tomasson, Michael H.
- Mohty, Mohamad
- Niesvizky, Ruben
- Nooka, Ajay K.
- Manier, Salomon
- Maisel, Christopher
- Jethava, Yogesh
- Martinez-Lopez, Joaquin
- Prince, H Miles
- Arnulf, Bertrand
- Rodriguez Otero, Paula
- Koehne, Guenther
- Touzeau, Cyrille
- Raje, Noopur
- Iida, Shinsuke
- Raab, Marc-Steffen
- Leip, Eric
- Sullivan, Sharon
- Conte, Umberto
- Viqueira, Andrea
- Lesokhin, Alexander M
- Titel
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
- Ist Teil von
- Blood, 2022-11, Vol.140 (Supplement 1), p.391-393
- Ort / Verlag
- Elsevier Inc
- Erscheinungsjahr
- 2022
- Quelle
- Alma/SFX Local Collection
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0006-4971eISSN: 1528-0020DOI: 10.1182/blood-2022-162440Titel-ID: cdi_crossref_primary_10_1182_blood_2022_162440
- Format
- –